The release of the market-based policy solutions coincided with the discussion at the Newseum in Washington, D.C.
Prime Therapeutics LLC (Prime) is one of the health care stakeholders involved in the CSRxP. The project is focused on sustainable prescription drug prices. Among the issues addressed in today's panel discussion with representatives from hospitals, health providers and benefit management plans were the cost of treatment, how medication prices are determined and the cost of developing new drugs.
"Soaring drug prices are a very real issue for many Americans — sometimes even detrimental to patients. Everyone in the industry needs to work toward solutions that help people get the medicine they need at a price that is affordable and sustainable," Prime Therapeutics President and CEO Jim DuCharme said. "As the only pharmacy benefit manager that's a member of CSRxP, Prime is working with coalition members to drive more competition, transparency, and value as those strategies can close the big gaps in today's health care system that are fueling out of control drug prices."
The platform provided by CSRxP provides the information policymakers need to help make prescription drugs affordable. It promotes competition in the marketplace. The group also recommends that policymakers provide more resources to the U.S. Food and Drug Administration (FDA) to speed approvals of generic drugs and assist in bringing new drugs to market.
“The strength of CSRxP is the diversity of members who have come together to advance solutions that address rising prescription drug prices,” National Coalition on Health Care President and CEO and CSRxP Executive Director John Rother said. “Our solutions have the support of hospitals, physicians, pharmacists, nurses, health plans, patients, and employers.”
Alerts Sign-up